Defining AI in Drug
The State Room Boston. MA. October 9th 2018
The second annual AI in Pharma Summit is purpose-built for the Innovators, Challengers, and Re-thinkers as AI and Machine Learning transform Pharmaceutical R&D.
Partners
Partners
Key Aims of the Summit
Refine and build
Develop and define how AI and machine learning will transform drug discovery and development.
Understand and Overcome
Decipher scientific and commercial challenges through case studies, workshops and discussions.
Collaborate and network
Bringing together senior executives to advance collaboration and partnerships.
Is The Event For You?
As AI continues to challenge the “unsustainability” of drug R&D, The AI in Pharma Summit will provide attendees with:
- First-hand knowledge of how both machine and deep learning are yielding previously unobtainable success in drug discovery, development and commercial outcomes.
- “Fly-on-the-wall” style insights from senior data and tech experts who have broken the mould in pharma.
- A network of like-minded peers seeking to overcome the same hurdles in AI adoption and application as you.
The AI in Pharma Summit is for those who are:
- Striving to uncover previously “undruggable” targets and leverage more insights from current data sets.
- Leading the next generation of commercial thinking at their organisations through more cost-effective strategies and solutions.
- Innovating the drug discovery and development model by harnessing disruptive technologies.
Who You Will Learn From
We will be putting the 2018 speaker faculty together in early 2018, in the meantime please take a look at the speakers from the 2017 event…
Pierre Leurent, CEO and founder of VOLUNTIS, has more than 19 years of international experience in digital health in the United States and Europe. Voluntis’ mission is to improve the real-world value of therapies by providing patients and clinicians with therapeutic companion software. Its clinical-grade, regulatory-cleared mobile and cloud solutions embed advanced real-time decision support algorithms to enable patients to better manage their treatment in remote collaboration with their healthcare team. Prior to starting Voluntis in 2001, Pierre worked at GE Medical Systems, where he took part in the development of medical imaging software. He also occupied several positions at HealthCenter Internet Services, a San Francisco-based vendor of electronic medical record solutions.
Marti Head is senior director of The Noldor and is building the Insights from Data team in the Platform Technology and Sciences (PTS) department of GSK Pharma R&D. Marti joined the computational chemistry group at GlaxoSmithKline in 1997, built and led the Philadelphia computational chemistry group from 2001 to 2007, and from 2007 to 2014 was the director of Computational Chemistry US, a 30-person, cross-site team responsible for proactively and creatively applying any and all computational technologies to drive programs across all of GSK’s therapeutic areas from target selection through to candidate selection. In May 2014, Marti took on a new role leading the Noldor, the collaborative GSK-Palantir team who are working closely together to embed this data integration and exploration platform widely throughout GSK. Marti is excited to be building the new Insights from Data team, whose mission is to provide the foundations, frameworks, tools, scientific insights, and innovative data analytics that will transform the way PTS uses and reuses data to drive decision making across the full spectrum of PTS accountabilities. Marti received her B.S. in Chemistry from Hamline University in St Paul MN, received her Ph.D. in Physical Chemistry from Duke University, and was a National Research Council postdoctoral fellow at the Center for Advanced Research in Biotechnology in Rockville MD.
Ed Addison co-founded Cloud Pharmaceuticals in 2009. Addison is a serial entrepreneur who founded three previous ventures, two of which successfully merged with public companies. He has a unique and strong blend of in-depth business and technical experience in biotechnology and in information technology. Addison holds an MS in Biomedical Engineering from Johns Hopkins University and MBA from Duke University Fuqua School of Business.
Ansu Bagchi leads the US Data Sciences and Applied Mathematics & Modeling groups at Merck. After earning his PhD in Operations Research at Rutgers Center for Operations Research, he was a mathematical sciences faculty at Worcester Polytechnic Institute. For the last 18 years at Merck Ansu has used applied mathematical techniques to aid decision making for research and development (e.g., lead identification/optimization), manufacturing (process innovation/optimization), human health (market access, patient benefits), and various corporate business processes.
Berton is Director of Data Science Research at Recursion Pharmaceuticals an emerging biotech company combining experimental biology and bioinformatics with artificial intelligence to discover new therapeutic opportunities for rare diseases. At Recursion, Berton leads the data science team in applying deep learning to data-rich images of cellular disease models in order to help the company reach its goal of treating 100 diseases by 2025. Prior to Recursion, Berton was Principal and Senior Scientist at Savvysherpa, a healthcare research and development firm; Director of Data Science at Red Brain Labs, a machine learning start-up automating decision making in business processes; and CTO of Perfect Pitch Technologies, a call center automation platform. Berton earned a PhD in mathematics from the University of Utah in 2007.
Brandon Allgood, CTO and Co-Founder at Numerate, Inc, manages the development and application of Numerate's AI platform and is responsible for Numerate’s technological vision. Brandon has also served as Director of Computational Science at Numerate and as a Research Scientist at Pharmix. He received a B.S. in Physics from the University of Washington, Seattle, and a Ph.D. in Computational Physics from the University of California, Santa Cruz. Brandon has authored scientific publications in astrophysics, solid-state physics, and computational biology and has 15 years of experience in large scale cloud and distributed computing, AI, and mathematical modelling. He is a member of the Forbes Technology Council and a UCSC Foundation Trustee.
Responsibility for Genome Sciences & Technologies reporting to the president of worldwide R&D, and a member of the worldwide R&D leadership team (WRDLT). As part of his responsibilities Morten oversees Pfizer’s human genetics, computational biomedicine & target validation, companion diagnostic and biospecimen management organizations. He also has responsibility for guiding Pfizer’s investments in platform technologies and is the R&D member on Pfizer’s big data operating committee. He was previously responsible for strategic technology and oncology collaborations as part of External R&D Innovation, and co-led several Pfizer-wide strategy initiatives on Precision Medicine and scientific technologies.
Juergen Schmider M.D., Ph.D. is a trained psychiatrist and clinical pharmacologist with 10 years of academic research and over 15 years of pharmaceutical industry experience. His research during his academic years included the neuroendocrinology of the hypophysis-pituitary-adrenal system at the Max Planck Institute, Munich, Germany as well as CYP mediated metabolism of psychoactive drugs at Tufts University Boston and Humboldt University Berlin. His industry experience led him from positions with increasing responsibility from Pfizer (Therapeutic Area Safety Head), Johnson & Johnson (VP Benefit Risk Management), Cephalon (Chief Safety Officer), Sanofi (VP Safety Surveillance and Risk Management), VP and Head of Global Product Safety at Hospria, and most recently VP, head of Safety Evaluation and Reporting in Worldwide Safety, Pfizer.
At Amgen, David works closely with the head of R&D and the CIO to provide operational and strategic leadership in support of Amgen’s worldwide initiatives in drug discovery and development. Previously, David was Vice President, Global Commercial Operations and Corporate Functions IS. David has also led Amgen’s International IS function based out of Zug, Switzerland, and before that, the IS group supporting Global Development functions. Prior to joining Amgen, David worked at Eli Lilly in various roles in Australia, New Zealand, and the US. David holds a Bachelor of Business from the University of Technology, Sydney.
Dr. Rodrigues, Ph.D., is an Associate Director of Advanced Analytics at Berg Analytics, a division of Berg Pharma, where he leads the research, development and internalization of disruptive analytical methodologies and IT platforms. With more than 15 years of experience in data analysis and biology, he streamlines innovations that translate information into actionable solutions. Prior, as a Postdoc at the Whitehead Institute-MIT, he combined computational, molecular and cell biology to study the molecular basis of tumor metastasis.
Andrea de Souza is the global business development lead for biopharmaceutical and healthcare AI startups at NVIDIA.
She is responsible for helping to drive the company’s growth and innovation strategies across the healthcare ecosystem. De Souza partners with thought leaders and organizations to accelerate the use of AI for evidence-based medicine.
De Souza has over 20 years of experience in working at the intersection of technology and the business of drug discovery, development, manufacture and commercialization. Prior to joining NVIDIA in 2016, she served in leadership positions at Janssen Pharmaceuticals, the Broad Institute of Harvard and MIT, and Amgen.
She is responsible for helping to drive the company’s growth and innovation strategies across the healthcare ecosystem. De Souza partners with thought leaders and organizations to accelerate the use of AI for evidence-based medicine.
De Souza has over 20 years of experience in working at the intersection of technology and the business of drug discovery, development, manufacture and commercialization. Prior to joining NVIDIA in 2016, she served in leadership positions at Janssen Pharmaceuticals, the Broad Institute of Harvard and MIT, and Amgen.
De Souza holds a Bachelor of Science in animal physiology from the University of California, Davis, a Master of Arts in health administration from the University of San Francisco, and an MBA from MIT Sloan School of Management. She also serves on an Informatics Advisory Committee for the National Institutes of Diabetes, Digestive Diseases and Kidney Diseases.
Andrea de Souza is the global business development lead for biopharmaceutical and healthcare AI startups at NVIDIA.
She is responsible for helping to drive the company’s growth and innovation strategies across the healthcare ecosystem. De Souza partners with thought leaders and organizations to accelerate the use of AI for evidence-based medicine.
De Souza has over 20 years of experience in working at the intersection of technology and the business of drug discovery, development, manufacture and commercialization. Prior to joining NVIDIA in 2016, she served in leadership positions at Janssen Pharmaceuticals, the Broad Institute of Harvard and MIT, and Amgen.
She is responsible for helping to drive the company’s growth and innovation strategies across the healthcare ecosystem. De Souza partners with thought leaders and organizations to accelerate the use of AI for evidence-based medicine.
De Souza has over 20 years of experience in working at the intersection of technology and the business of drug discovery, development, manufacture and commercialization. Prior to joining NVIDIA in 2016, she served in leadership positions at Janssen Pharmaceuticals, the Broad Institute of Harvard and MIT, and Amgen.
De Souza holds a Bachelor of Science in animal physiology from the University of California, Davis, a Master of Arts in health administration from the University of San Francisco, and an MBA from MIT Sloan School of Management. She also serves on an Informatics Advisory Committee for the National Institutes of Diabetes, Digestive Diseases and Kidney Diseases.
Deborah Profit has worked in pharmaceutical industry for over two decades and is currently the Vice President, Otsuka Information Technology (OIT) at Otsuka Pharmaceuticals. In this role, Dr. Profit is responsible for the commercial, enterprise and research and development arms of the Otsuka IT organization. In her current role, Dr. Profit is responsible for the executive sponsorship of creative solutions across technical, commercial and clinical development teams. Dr. Profit also plays a key leadership role in transitioning pilots and prototypes to full-scale projects to leverage solutions globally that complement the business portfolio to include digital medicine, digital health and big data platforms. Dr. Profit possesses undergraduate degrees in nursing and psychology, a Master of Science in Regulatory Affairs - Drugs, Biologics and Medical Device, and a Doctorate in Leadership Studies with a concentration in Innovation and Creativity.
Jaquie is Head of Digital Health at Cambridge Consultants and leads the initiative to provide strategic guidance and practical support for clients transitioning their business model to include a digital element. These digital elements include device connectivity, data science, launch strategies, behavioural science and digital service design.
Jaquie has a BSc in Applied Biology, 10 years’ experience in Molecular Biology and 15 years’ experience of Product Management and Marketing for software, hardware and digital services in medical and life science industries that include immunology, ophthalmology, neuroscience and bioinformatics. Jaquie has also worked in telecommunications, food hygiene and intelligence informatics.
Jaquie is a member of the Chartered Institute of Marketing (CIM).
What Will I Learn?
Click to download our full event agenda.
8:00 Registration, Breakfast & Networking
State of Play in the Industry: AI in Pharma
9:00 Chairman’s Opening Remarks & Setting the Scene
Eric Neumann, CEO & Founder, AIDAKA Consulting
9:10 The Beginning of the AI Revolution in Pharma: Building a Pipeline by AI-Driven Discovery
Slava Akmaev, Senior Vice President & Chief Analytics Officer; Chief Executive Officer, Berg Health
Leonardo Rodrigues, Associate Director, Advanced Analytics, Berg Health
09:40 Keynote Panel and Open Q&A: What’s Holding Back the Application of AI in Pharma?
Ron Alfa, Vice President, Discovery & Product; Chief Executive Officer, Recursion Pharmaceuticals
Slava Akmaev, Senior Vice President & Chief Analytics Officer, Berg Health
Andrea de Souza, Global Business Development Lead, Healthcare, NVIDIA
Morten Sogaard, Vice President & Head, WRD Genome Sciences & Technologies, Pfizer
10:20 Speed Networking & Morning Refreshments
Research Showcase – How and Where is AI Achieving Success?
11:20 Is AI the “Holy Grail” of Drug Discovery?
Ed Addison, Chairman & Chief Executive Officer, Cloud Pharmaceuticals
11:45 Drug Discovery from Images: High-Throughput Phenotypic Assays and Deep Learning
Berton Earnshaw, Director, Data Science Research, Recursion Pharmaceuticals
12:10 Exploring R&D Applications in Machine Learning
Wei-Yi Cheng, Senior Data Scientist, Roche
12:35 AI Application in Pharmacovigilance: Case Processing Automation
Juergen Schmider, Vice President, Safety Evaluation & Reporting, Pfizer
1:00 AI Under Your Skin
Andrea de Souza, Global Business Development Lead, Healthcare, NVIDIA
1:25 Long-Table Lunch & Networking
Deep Dive Workshops
2:40 Harborside 3 – Workshop 1: A Beginners Guide – What’s Inside the Black Box of AI?
The goal of this interactive workshop is for attendees to understand the first steps to take when beginning to use AI and machine learning to improve drug discovery and development.
Brandon Allgood, Chief Technology Officer, Numerate
2:40 Harborside 4 – Workshop 2: Collaborating with Solution Providers
This collaborative workshop will allow drug discoverers, developers and commercial leaders to discuss the factors for success when partnering and working with AI tech developers. We’ll adopt a holistic approach and think about the entire process from identification of the business problem and data, through model building and validation, and on to deployment and utilization of the results.
Greg Landrum, VP, Life Sciences, KNIME
4:45 Panel Discussion and Open Q&A: What is the Best Practice for Partnerships to Advance Digital Therapeutics and Digital Medicine?
Bozidar Jovicevic, Vice President, Global Head of Digital Medicines Sanofi
Michelle Marlborough, Chief Product Officer AiCure
Nicole Mowad-Nassar, Vice President & Head, U.S. Business Operations & External Partnerships Takeda
Gabriel Vargas, Executive Medical Director, Mobile Health & Neuroscience TA Head Amgen
3:40 Afternoon Refreshments
Shaping the Future of AI in Pharma
4:10 Key Learning from All Interactive Workshops
4:30 Closing Panel and Open Q&A: Shaping the Future of AI in Pharma
Ed Addison, Co-Founder, Chairman & Chief Executive Officer, Cloud Pharmaceuticals
Ansu Bagchi, Director, Head of US Data Science & Applied Mathematics, Merck
David Christie, Vice President, Research & Development Informatics, Amgen
Martha Head, Head, Insights from Data, GSK
5:20 Chairman’s Summary
Eric Neumann, CEO & Founder, AIDAKA Consulting
5:30 Drinks Reception
7:00 Close of AI in Pharma Summit 2017
We will be finalising the programme for the 2018 summit in the early part of 2018. In the meantime, please take a look at the programme from the 2017 summit. This will give you a good idea of the format of our summit and the quality of our speaker faculty.
The Venue
The AI in Pharma Summit takes place in the inspiring State Room, situated on the 33rd Floor of the Sixty State Street skyscraper in downtown Boston.
Panoramic windows, mahogany floors and state of the art lighting ensure that this purpose built venue will enhance your learning experience.
Our main sessions will take place in the Harbor Rooms. The long-table lunch will offer a change of scenery and is hosted in the City Room. Everything you will need for the day is located on the same floor. We even have a chill zone for delegates, who want to reflect, rest or just catch up with e-mail.
We’ve worked closely with our caterers to ensure you have everything you need for the day. From brain fuel at the innovation breakfast to relaxing drinks at the end of the day, everything is designed to enhance your experience.
Accommodation is not available at the venue, but there is a wide variety of hotels within short walking distance.
Full details of the venue location, hotels, catering and travel will be included in your registration pack.
Registration
Sponsorship
The 2017 summit exceeded all expectations and the 2018 summit is attracting considerable interest.
The success of the 2017 summit was down to the high-class programme and the quality of the audience. Registrations were only accepted from applicants who were appropriate for the summit and delegates from vendor companies were not permitted.
This ensured that the audience of senior decision makers were able to meet with a selected group of relevant suppliers. Our 2017 sponsors tell us that they made significant inroads into target companies and advanced their sales pipelines.
For further information, or to have an informal discussion regarding sponsorship opportunities, please contact Nick Alderslade on 020 3865 9030 or nick@greygreenmedia.com
2017 Audience Breakdown
2017 Audience Job Title
Register For The Event
For pricing and booking options please click the button to go to the registration page.
Registration
